786 related articles for article (PubMed ID: 30556751)
21. CD73: a novel target for cancer immunotherapy.
Zhang B
Cancer Res; 2010 Aug; 70(16):6407-11. PubMed ID: 20682793
[TBL] [Abstract][Full Text] [Related]
22. Targeting Immunometabolism Mediated by CD73 Pathway in
Passarelli A; Aieta M; Sgambato A; Gridelli C
Front Immunol; 2020; 11():1479. PubMed ID: 32760402
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer.
Zhou Q; Ding W; Qian Z; Zhu Q; Sun C; Yu Q; Tai Z; Xu K
Mol Pharm; 2021 Nov; 18(11):4015-4028. PubMed ID: 34648293
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.
Figueiró F; de Oliveira CP; Bergamin LS; Rockenbach L; Mendes FB; Jandrey EH; Moritz CE; Pettenuzzo LF; Sévigny J; Guterres SS; Pohlmann AR; Battastini AM
Purinergic Signal; 2016 Jun; 12(2):303-12. PubMed ID: 26910734
[TBL] [Abstract][Full Text] [Related]
25. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
26. The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy.
Jiang X; Wu X; Xiao Y; Wang P; Zheng J; Wu X; Jin Z
Front Immunol; 2023; 14():1110325. PubMed ID: 36776866
[TBL] [Abstract][Full Text] [Related]
27. CD8
Panigrahi S; Bazdar DA; Albakri M; Ferrari B; Antonelli CJ; Freeman ML; Dubyak G; Zender C; Sieg SF
Eur J Immunol; 2020 Dec; 50(12):2055-2066. PubMed ID: 32548862
[TBL] [Abstract][Full Text] [Related]
28. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
29. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret L; Pommey S; Allard B; Garaud S; Bergeron M; Cousineau I; Ameye L; Bareche Y; Paesmans M; Crown JPA; Di Leo A; Loi S; Piccart-Gebhart M; Willard-Gallo K; Sotiriou C; Stagg J
Ann Oncol; 2018 Apr; 29(4):1056-1062. PubMed ID: 29145561
[TBL] [Abstract][Full Text] [Related]
31. Downregulation of CD73 associates with T cell exhaustion in AML patients.
Kong Y; Jia B; Zhao C; Claxton DF; Sharma A; Annageldiyev C; Fotos JS; Zeng H; Paulson RF; Prabhu KS; Zheng H
J Hematol Oncol; 2019 Apr; 12(1):40. PubMed ID: 31014364
[TBL] [Abstract][Full Text] [Related]
32. Targeting adenosine for cancer immunotherapy.
Leone RD; Emens LA
J Immunother Cancer; 2018 Jun; 6(1):57. PubMed ID: 29914571
[TBL] [Abstract][Full Text] [Related]
33. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Chen Q; Pu N; Yin H; Zhang J; Zhao G; Lou W; Wu W
J Cell Mol Med; 2020 Aug; 24(15):8674-8686. PubMed ID: 32643277
[TBL] [Abstract][Full Text] [Related]
34. Ecto-5'-nucleotidase (CD73) promotes tumor angiogenesis.
Wang L; Tang S; Wang Y; Xu S; Yu J; Zhi X; Ou Z; Yang J; Zhou P; Shao Z
Clin Exp Metastasis; 2013 Jun; 30(5):671-80. PubMed ID: 23508889
[TBL] [Abstract][Full Text] [Related]
35. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
36. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
37. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
38. Modeling codelivery of CD73 inhibitor and dendritic cell-based vaccines in cancer immunotherapy.
Arabameri A; Pourgholaminejad A
Comput Biol Chem; 2021 Dec; 95():107585. PubMed ID: 34610532
[TBL] [Abstract][Full Text] [Related]
39. Advances in CD73 inhibitors for immunotherapy: Antibodies, synthetic small molecule compounds, and natural compounds.
Zhang M; Dai X; Xiang Y; Xie L; Sun M; Shi J
Eur J Med Chem; 2023 Oct; 258():115546. PubMed ID: 37302340
[TBL] [Abstract][Full Text] [Related]
40. Identification of a regulatory Vδ1 gamma delta T cell subpopulation expressing CD73 in human breast cancer.
Chabab G; Barjon C; Abdellaoui N; Salvador-Prince L; Dejou C; Michaud HA; Boissière-Michot F; Lopez-Crapez E; Jacot W; Pourquier D; Bonnefoy N; Lafont V
J Leukoc Biol; 2020 Jun; 107(6):1057-1067. PubMed ID: 32362028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
